4A4E96B0-5AC6-4B7D-AB1C-F814C338589C
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 39.7503285151117
- age_years
- 32
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.568
- G2M_CHECKPOINT+0.423
- TGF_BETA_SIGNALING+0.418
- MITOTIC_SPINDLE+0.400
- MYC_TARGETS_V1+0.388
- PROTEIN_SECRETION+0.385
- E2F_TARGETS+0.378
- MYC_TARGETS_V2+0.354
- WNT_BETA_CATENIN_SIGNALING+0.314
- UNFOLDED_PROTEIN_RESPONSE+0.307
Top 10 suppressed
- KRAS_SIGNALING_DN-0.373
- MYOGENESIS-0.307
- COAGULATION-0.292
- SPERMATOGENESIS-0.286
- INFLAMMATORY_RESPONSE-0.261
- INTERFERON_GAMMA_RESPONSE-0.258
- ALLOGRAFT_REJECTION-0.256
- INTERFERON_ALPHA_RESPONSE-0.241
- PANCREAS_BETA_CELLS-0.221
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.205
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 7779D220-647F-4D6C-890B-022208B51F57 | — | — | 0.929 |
| 2 | 07463FB6-787C-4FAC-8954-C694EEF27F69 | — | — | 0.919 |
| 3 | SRR934724 | — | — | 0.912 |
| 4 | 1F4B7E2E-E242-410A-AE78-8FC412D3C0A9 | — | — | 0.907 |
| 5 | A1E55AC6-A41F-454A-A3B6-8F49D2AAFEF2 | — | — | 0.907 |
| 6 | 4A2E75AE-A92F-4497-9253-64AC42CFA745 | — | — | 0.905 |
| 7 | 24F914FE-3DF0-4286-9231-9D525A777306 | — | — | 0.905 |
| 8 | B7B9B5C1-C11D-47B8-B2F8-A5660AB961C1 | — | — | 0.903 |
| 9 | SRR934789 | — | — | 0.901 |
| 10 | SRR934777 | — | — | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.568 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.423 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.418 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.388 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.385 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.378 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.354 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.314 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.307 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.306 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.256 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.217 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.189 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.169 | Inavolisib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.067 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.066 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.058 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.056 | Temsirolimus | — uncovered |